NorthStar Medical Radioisotopes Executes Supply Agreement With Cellectar Biosciences for Therapeutic Radioisotope Actinium-225 (Ac-225)Business Wire • 1h
Cellectar Biosciences Reports Financial Results for Q3 2024 and Provides a Corporate UpdateGlobeNewsWire • Monday
Cellectar Biosciences and NorthStar Medical Radioisotopes Announce Partnership for Supply of Actinium-225GlobeNewsWire • 11/14/24
Cellectar Biosciences and SpectronRx Partner to Manufacture Novel Phospholipid Radioconjugate for the Treatment of CancerGlobeNewsWire • 11/12/24
Cellectar Biosciences to Report Third Quarter Financial Results and Host a Conference Call on Monday, November 18, 2024GlobeNewsWire • 11/11/24
Cellectar Selected to Present New Data from Phase 2 CLOVER-WaM Study in Oral Session at ASH 2024GlobeNewsWire • 11/07/24
Cellectar Biosciences to Present at IWWM Featuring Iopofosine I 131Zacks Investment Research • 08/30/24
Iopofosine I 131 Featured in Two Separate Presentations at 12th International Workshop on Waldenstrom's MacroglobulinemiaGlobeNewsWire • 08/26/24
Cellectar to Restate Previously Issued Financial Statements – Company Announces Receipt of Expected Delinquency Notification Letter from NasdaqGlobeNewsWire • 08/23/24
Cellectar Biosciences Reports Financial Results for Q2 2024 and Provides a Corporate UpdateGlobeNewsWire • 08/13/24
UPDATE -- Cellectar Biosciences to Announce Second Quarter Financial Results and Host a Conference Call on Tuesday, August 13, 2024GlobeNewsWire • 08/08/24
Cancer-Focused Cellectar Biosciences Stock Trades Lower Despite Meeting Goal In Blood Cancer StudyBenzinga • 07/23/24
Cellectar Biosciences' Iopofosine I 131 Exceeds Primary Endpoint in Waldenstrom's Macroglobulinemia Pivotal Study with 78% of Major Response Patients Remaining Progression Free at 18 MonthsGlobeNewsWire • 07/23/24
Cellectar Biosciences Announces Exercise of Tranche B Warrants and Purchase of New Warrants for Approximately $19.4 million with the Potential to Raise Up to an Additional $73.3 MillionGlobeNewsWire • 07/22/24
Cellectar Biosciences to Host Key Opinion Leader Event to Review the Full Results from Its CLOVER WaM Pivotal Trial and Waldenstrom's Macroglobulinemia Market LandscapeGlobeNewsWire • 06/27/24
Cellectar Biosciences and City of Hope Cancer Center Enter Collaboration to Evaluate Iopofosine I 131 in Mycosis FungoidesGlobeNewsWire • 05/29/24
Cellectar Biosciences Reports Financial Results for Q1 2024 and Provides a Corporate UpdateGlobeNewsWire • 05/14/24
Cellectar Biosciences to Present at the Guggenheim Healthcare Talks Radiopharmaceuticals DayGlobeNewsWire • 05/08/24